|
|
View Clinical Trial (Medical Research Study)
|
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women - NCT00697463-10032 (Clinical Trial 225958)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy225958.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
New York |
|
State:
|
|
NY |
| Zip Code: |
|
10032 |
| Conditions: |
|
Premenopause - Low Bone Density - Fracture - Osteoporosis |
| Purpose: |
|
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young
individuals sustain one or more low-trauma fractures. Teriparatide [PTH(1-34)], which is FDA
approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating
bone formation. We hypothesize that teriparatide will significantly increase bone density
(BMD) and improve bone structure in premenopausal women with IOP.
|
| Study summary: |
|
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young
individuals sustain one or more low-trauma fractures. In our studies of IOP in men,
histomorphometric indices of bone formation are depressed, and affected men respond to
PTH(1-34) with robust increases in lumbar spine (LS) bone mineral density (BMD). We are now
beginning the third year of an R01 (AR4989603) investigating the etiology and pathogenesis,
as well as the histomorphometric and bone microarchitectural features of IOP in
premenopausal women. We have found evidence of markedly decreased bone formation and
microarchitectural deterioration with decreased mechanical competence/strength.
Teriparatide [PTH(1-34)] is an anabolic agent that stimulates bone formation and improves
bone microarchitecture. Based upon our findings, we hypothesize that teriparatide will
significantly increase BMD and improve microarchitecture in premenopausal women with IOP.
We will test this hypothesis in an open-label study of carefully characterized premenopausal
women with IOP who are participating in our NIH-funded study and who have fragility
fractures or very low bone density. Participants in the study will receive 18 months of
teriparatide and the effects on BMD and microstructure, bone mechanical competence, and bone
turnover will be assessed. In order to assess whether teriparatide stimulates bone formation
to the same extent in women with IOP as it does in normal women, we will compare the
short-term changes (2 and 4 weeks) in biochemical markers of bone formation in response to
teriparatide between women with IOP and normal women who are participating in our NIH-funded
study as controls. |
| Criteria: |
|
Inclusion Criteria:
- Premenopausal women of all races
- Ages 20 to 48
- Regular menses (at least 8 periods in the last 12 months).
- FSH < 20 mIU/ml during the early follicular phase, to exclude women in the
perimenopause.
- Fracture subjects: documented low trauma fracture(s) at age >= 18 (e.g., fracture
associated with a fall from a standing height or less).
- Low BMD subjects: DXA BMD T score less than or equal to 2.5 at the LS, total hip,
femoral neck or distal radius, who have not had a fracture
- Control subjects: DXA BMD T score greater than or equal to 1.0 at the LS, total hip,
femoral neck and distal radius, who have not had a fracture.
- All subjects must use appropriate birth control methods to prevent pregnancy for the
duration of teriparatide treatment.
Exclusion Criteria:
- Secondary Causes of Osteoporosis
- Disorders of mineral metabolism: primary or secondary hyperparathyroidism (serum
intact PTH > 65 pg/ml), vitamin D deficiency (serum 25OHD < 30 ng/ml), hypercalciuria
(>300 mg/g creatinine), Paget's disease, clinical osteomalacia, osteogenesis
imperfecta (OI).
- Recent pregnancy or lactation (within past year).
- Prolonged amenorrhea (> 6 months) during reproductive years (except during pregnancy
or lactation).
- History of anorexia nervosa.
- Malignancy, except cured basal or squamous cell skin carcinoma.
- Endocrinopathy: hyperthyroidism (elevated serum thyroxine and/or suppressed TSH),
untreated hypothyroidism, Cushing's syndrome, prolactin-secreting pituitary adenoma.
- Renal insufficiency (serum creatinine above upper limit of female normal range).
- Liver disease (AST, ALT, bilirubin, total alkaline phosphatase activity above upper
normal limit).
- Intestinal disorders (celiac disease, pancreatic insufficiency, inflammatory bowel
disease).
- History or current use of glucocorticoids, anticonvulsants, anticoagulants,
diuretics, methotrexate.
- Current use of depot preparations of progesterone or GnRH agonists.
- Current use of drug therapies for osteoporosis (estrogen preparations other than
contraceptives, raloxifene, bisphosphonates, calcitonin, PTH). Subjects who agree to
discontinue use of these medications will be eligible to participate 6 months after
discontinuing raloxifene or calcitonin, and 12 months after discontinuing
bisphosphonates. Total exposure to bisphosphonates must be < 1 year. Subjects who
have taken PTH at any time in the past will not be eligible.
- Additional contraindications to teriparatide use: Unexplained elevated total or bone
specific alkaline phosphatase or prior external beam or implant radiation therapy
involving the skeleton. |
|
|
|
| Study is available at: |
|
Columbia University Medical Center
New York, NY 10032
United States
Primary Contact:
Halley F Eisenberg, MPH
Email: hfe2101@columbia.edu
Phone: 212-305-7225 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|